NLRP3 and amyotrophic lateral sclerosis: In a clinical study performed on patients with ALS, GSDMD antibody reactivity was demonstrated in the motor cortex and white matter, as well as increased NLRP3 expression in microglia (Van Schoor et al., 2022).